首页> 外文OA文献 >Reduction of Antibody Response to an 11-Valent Pneumococcal Vaccine Coadministered with a Vaccine Containing Acellular Pertussis Components
【2h】

Reduction of Antibody Response to an 11-Valent Pneumococcal Vaccine Coadministered with a Vaccine Containing Acellular Pertussis Components

机译:减少对11价肺炎球菌疫苗与含有脱细胞百日咳成分的疫苗联合使用的抗体应答

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In pneumococcal conjugate vaccines (PCVs), polysaccharide antigens are often conjugated to protein carriers related to other common vaccines. It is therefore important to test PCV interaction with other pediatric vaccines when administered simultaneously. We assessed the immune response to an 11-valent PCV conjugated to diphtheria and tetanus carriers (PncD/T11), administered concomitantly, but in separate sites, with a combined vaccine containing epitopes related antigenically to the carriers: polyribosylribitol phosphate-tetanus tox oid (PRP-T), diphtheria toxoid (DT), and tetanus toxoid (TT). In addition, these combinations contained inactivated poliovirus vaccine (IPV) and either whole-cell pertussis (wP) or acellular pertussis (aP) components. After coadministration of PncD/T11 with the combined vaccine containing wP (DTwP/IPV/PRP-T), the responses to all polysaccharides in the PncD/T11 were satisfactory. In contrast, when coadministered with an aP-containing combination (DTaP/IPV/PRP-T), the response to all seven pneumococcal conjugates to TT was significantly reduced after primary and booster immunization. The pneumococcal conjugates to DT were not significantly reduced after the primary series, but were somewhat reduced after booster. It is likely that some suppression of the tetanus-mediated response occurred even when the PncD/T11 was coadministered with wP, but this suppression was masked by the adjuvant effect of wP. By replacing wP with aP, this adjuvant effect was removed, unmasking the suppression of the tetanus-mediated response. With the increasing use of multiple aP-containing vaccines in infancy, novel approaches to adjuvants and carrier protein technology are likely to be required.
机译:在肺炎球菌结合疫苗(PCV)中,多糖抗原通常与与其他常见疫苗相关的蛋白质载体结合。因此,当同时给药时,测试PCV与其他儿科疫苗的相互作用非常重要。我们评估了与白喉和破伤风载体(PncD / T11)共轭的11价PCV的免疫应答,该疫苗同时但在不同部位施用,并含有与抗原相关的抗原决定簇的组合疫苗:多核糖基核糖醇磷酸-破伤风类毒素( PRP-T),白喉类毒素(DT)和破伤风类毒素(TT)。另外,这些组合包含灭活的脊髓灰质炎病毒疫苗(IPV)和全细胞百日咳(wP)或无细胞百日咳(aP)成分。将PncD / T11与含wP的组合疫苗(DTwP / IPV / PRP-T)共同给药后,对PncD / T11中所有多糖的反应均令人满意。相反,当与含aP的组合(DTaP / IPV / PRP-T)并用时,初次和加强免疫后,对所有7种肺炎球菌结合物对TT的反应均明显降低。肺炎球菌与DT的结合物在主要系列试验后并未显着降低,但在加强免疫后有所降低。即使将PncD / T11与wP并用,破伤风介导的反应也可能会受到一定程度的抑制,但这种抑制被wP的辅助作用所掩盖。通过用aP取代wP,该佐剂作用被消除,从而掩盖了对破伤风介导的反应的抑制作用。随着婴儿期多种含aP疫苗的使用的增加,可能需要新的佐剂和载体蛋白技术方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号